Ikena Oncology (IMA) - Business Payback Period
The R&D potential of ImageneBio Inc (IMA) is based on the creation of tumor metabolism inhibitors and targeted therapies, while the current standalone P/E ratio stands at -0.80. This chart of the current market value confirms the stability of development cycles, complemented by strict climate control during molecule transportation. The brand's high authority within the scientific community is driven by the efficacy of its methods for the precision destruction of resistant neoplasms.
Analytical breakdowns for ImageneBio Inc
- share price and expert price forecast:
- market capitalization indicators:
- book capitalization data:
- company liabilities and liquidity data:
- company profitability and valuation multiples indicators:
IMA - Net Profit|Projected Future Earnings ImageneBio Inc|IMA - P/E Multiple|Forward Price to Earnings Multiple Ikena Oncology, Inc.|IMA - PEG Multiple|Company Value to EBITDA ImageneBio Inc|IMA - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Ikena Oncology|IMA - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months ikenaoncology.com|IMA - Earnings growth in current year|Net earnings per share growth forecast for next year ImageneBio Inc
Summary company analysis:IMA (ikenaoncology.com)
A conservative approach to the fundamental analysis of ImageneBio Inc (IMA) requires separating market speculation from the actual business value. The ratio of market capitalization to net income, reflected in the issuer's P/E history, measures the investment payback period, which is critical for a biotech company whose margins are temporarily constrained by high R&D costs and the pre-profit stage of clinical trials for oncology drugs.
Key competitors
ARGX: Company Value to Net Income|P/E Multiple BNTX|Business Payback Period ABIVAX|Price to Earnings Ratio ADMA Bio ADMA|PTGX - Price to Earnings Ratio|IMVT - Price to Earnings Ratio|kiniksa.com (KNSA) - Price to Earnings Ratio|GRFS (Grifols) - Price to Earnings Ratio|Adaptive Biotech (ADPT) - P/E Multiple|Price to Earnings Ratio Celldex|Price to Earnings Multiple AUPH (Aurinia Corp)|P/E Multiple BCRX|VERA - Market Cap to Earnings|P/E Multiple DNTH (Dianthus Therapeutics, Inc.)|Business Payback Period Pharvaris NV (PHVS)|ABCL - Price to Earnings Ratio|Tourmaline (TRML) - Price to Earnings Ratio|PGEN: P/E Multiple|pharming.com (PHAR) - P/E Multiple|NKTR (Nektar Therapeutics Inc.) - P/E Multiple|UPB - Market Cap to Net Income Ratio|P/E Multiple ZBIO|IMNM - Market Cap to Earnings|Price to Earnings Ratio Gossamer Bio, Inc. GOSS|KALV: Price to Earnings Multiple|Septerna - P/E Multiple|Market Cap to Earnings Pieris Pharma|SVRA: P/E Multiple|RIGL (Rigel Corp) - Price to Earnings Ratio|ANAB (AnaptysBio, Inc.) - P/E Multiple|astriatx.com (ATXS) - Business Payback Period|Price to Earnings Ratio enGene (ENGN)|RAPT - Market Cap to Earnings|Aerovate Therapeutics - Price to Earnings Ratio|Company Value to Net Income ACRS|Kyverna Therapeutics - P/E Multiple|Business Payback Period tizianalifesciences.com TLSA|Cabaletta Bio (CABA) - Price to Earnings Ratio|Price to Earnings Multiple VTYX|THTX (Theratechnologies Inc) - P/E Multiple|Price to Earnings Ratio Avalo Therapeutics Inc (AVTX)|P/E Multiple ELDN|Business Payback Period agenusbio.com|Price to Earnings Ratio Climb Bio CLYM|ZURA - Price to Earnings Ratio|aTyr - P/E Multiple|ADAG - P/E Multiple|shattucklabs.com (STTK) - Price to Earnings Ratio|Market Cap to Net Income EQ (Equillium)|CNTB (Connect Biopharma Holdings) - P/E Multiple|IMUX: Company Value to Net Income|P/E Multiple ATRA|P/E Multiple inflarx.de (IFRX)|Price to Earnings Ratio X4 Pharmaceuticals XFOR|Company Value to Net Income ACET|CELU - Price to Earnings Ratio|INmune Bio Inc (INMB) - Price to Earnings Ratio|BRNS: P/E Multiple|Kezar Life Sciences Inc (KZR) - P/E Multiple|Price to Earnings Ratio SABS|AKTX: Company Value to Net Income|P/E Multiple ENLV|Business Payback Period q32bio.com|Price to Earnings Ratio GeoVax Labs Inc GOVX|EDSA - Price to Earnings Ratio|IBIO - Price to Earnings Ratio|Carisma Therapeutics (CARM) - Price to Earnings Ratio|XTLB (XTL Biopharmaceuticals Ltd.) - Price to Earnings Ratio|Bolt Biotherapeutics, Inc. (BOLT) - P/E Multiple|Price to Earnings Ratio HCW Biologics, Inc.|Price to Earnings Multiple APVO (Aptevo)|P/E Multiple AIM|ADTX - Market Cap to Earnings|P/E Multiple GRI (GRI Bio)|Business Payback Period XORTX Therapeutics Inc (XRTX)|HIND - Price to Earnings Ratio|Revelation Biosciences Corp (REVB) - Price to Earnings Ratio|INDP: P/E Multiple|scinai.com (SCNI) - P/E Multiple|CALI (CalciMedica Inc) - P/E Multiple|AFMD - Market Cap to Net Income Ratio|P/E Multiple ALLK|HOOK - Market Cap to Earnings|Price to Earnings Ratio IGM Biosciences IGMS|ITOS: Price to Earnings Multiple|Ocean Biomedical - P/E Multiple|Market Cap to Earnings TC BioPharm (Holdings) Plc|THRD: P/E Multiple
